Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Instagram Outage Disrupts Thousands of U.S. Users 
HAMPTON, N.J., Aug. 02, 2017 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2017 financial results on Tuesday, August 8, 2017 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to review the second quarter 2017 financial results and to provide an update on key research and development and business objectives for the remainder of 2017.
The conference call and presentation will be webcast live over the Internet and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com. The call can also be accessed by dialing (866) 743-9666 (within the United States) or (760) 298-5103 (outside the United States). The passcode is 52336196.
A replay of the call will be available approximately two hours after the live call concludes through August 15, 2017. To access the replay, dial (855) 859-2056 (within the United States) or (404) 537-3406 (outside the United States). The passcode is 52336196. The webcast will also be archived on the Company's website.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Company Contact Sarah Cavanaugh Senior Vice President, Corporate Affairs and Administration Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Associate Director, Investor Relations & Corp Communications Celldex Therapeutics, Inc. (617) 383-3433 [email protected]
